Can a lower dose keep leukemia in check? new study aims to find out
Disease control
ENROLLING_BY_INVITATION
This study looks at whether reducing the dose of the drug olverembatinib can still keep chronic myeloid leukemia (CML) under control in patients who have already responded well to treatment. About 100 adults with CML in chronic or accelerated phase will take a lower dose (20 mg e…
Sponsor: Qian Jiang • Aim: Disease control
Last updated May 15, 2026 11:56 UTC